Literature DB >> 24803888

Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective.

Nadia Harbeck1, Norbert Marschner2, Michael Untch3, Thomas Decker4, Susanna Hegewisch-Becker5, Christian Jackisch6, Jens Huober7, Hans-Joachim Lück8, Gunter von Minckwitz9, Anton Scharl10, Andreas Schneeweiss11, Hans Tesch12, Anja Welt13, Rachel Wuerstlein14, Christoph Thomssen15.   

Abstract

The Advanced Breast Cancer Second International Consensus Conference (ABC2) on diagnosis and treatment of advanced breast cancer took place in Lisbon, Portugal, on November 7-9, 2013. The focus of the conference was inoperable, locally advanced breast cancer. The diagnosis and treatment of metastatic breast cancer had already been discussed 2 years before at the ABC1 Consensus and were only updated regarding special issues as part of this year's ABC2 Consensus. Like 2 years ago, a working group of German breast cancer experts commented on the voting results of the ABC panelists, with special consideration of the German guidelines for the diagnosis and treatment of breast cancer (German Gynecological Oncology Working Group (AGO) recommendations, S3 Guideline) in order to adapt them for daily clinical practice in Germany. The goal of both the ABC Consensus and the German comments is to facilitate evidence-based therapy decisions.

Entities:  

Keywords:  AGO; Consensus; LABC; Locally advanced breast cancer; MBC; Metastatic breast cancer

Year:  2014        PMID: 24803888      PMCID: PMC3995369          DOI: 10.1159/000358689

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  4 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

Review 3.  Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.

Authors:  Nadia Harbeck; Rachel Wuerstlein
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

4.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

  4 in total
  4 in total

Review 1.  Systemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelines.

Authors:  A A Joy; M Ghosh; R Fernandes; M J Clemons
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

2.  Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.

Authors:  George Notas; Vassiliki Pelekanou; Marilena Kampa; Konstantinos Alexakis; Stelios Sfakianakis; Aggelos Laliotis; John Askoxilakis; Eleftheria Tsentelierou; Maria Tzardi; Andreas Tsapis; Elias Castanas
Journal:  Mol Oncol       Date:  2015-06-05       Impact factor: 6.603

Review 3.  Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant.

Authors:  Iben Kümler; Ann S Knoop; Christina A R Jessing; Bent Ejlertsen; Dorte L Nielsen
Journal:  ESMO Open       Date:  2016-08-16

4.  Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Authors:  Denise A Yardley; Adam Brufsky; Robert E Coleman; Pierfranco F Conte; Javier Cortes; Stefan Glück; Jean-Mark A Nabholtz; Joyce O'Shaughnessy; Robert M Beck; Amy Ko; Markus F Renschler; Debora Barton; Nadia Harbeck
Journal:  Trials       Date:  2015-12-16       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.